Tissue factor pathway inhibitor (TFPI) release after heparin stimulation is increased in Type 1 diabetic patients with albuminuria

Autor: Karly Hamulyák, R. van Oerle, P. B. Leurs, Bruce H. R. Wolffenbuttel
Přispěvatelé: University of Groningen, Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Center for Liver, Digestive and Metabolic Diseases (CLDM), Interne Geneeskunde, RS: NUTRIM School of Nutrition and Translational Research in Metabolism, RS: CARIM School for Cardiovascular Diseases
Jazyk: angličtina
Rok vydání: 2003
Předmět:
Adult
Male
microvascular complications
VONWILLEBRAND-FACTOR
medicine.medical_specialty
NEPHROPATHY
Endocrinology
Diabetes and Metabolism
Lipoproteins
Thrombomodulin
COAGULATION
Tissue plasminogen activator
endothelial dysfunction
MELLITUS
Endocrinology
Tissue factor pathway inhibitor
Von Willebrand factor
Internal medicine
von Willebrand Factor
Internal Medicine
medicine
Albuminuria
Humans
haemostatic parameters
HUMAN-PLASMA
GLYCOSAMINOGLYCANS
biology
business.industry
Heparin
PLASMINOGEN-ACTIVATOR INHIBITOR
Area under the curve
MICROALBUMINURIA
medicine.disease
Diabetes Mellitus
Type 1
Tissue Plasminogen Activator
GLOMERULAR BASEMENT-MEMBRANE
biology.protein
tissue factor pathway inhibitor
Microalbuminuria
Female
SULFATE PROTEOGLYCAN
medicine.symptom
atherosclerosis
business
Plasminogen activator
medicine.drug
Zdroj: Diabetic Medicine, 20(1), 16-22. Wiley
ISSN: 0742-3071
Popis: Department of Internal Medicine, University Hospital, Maastricht, The Netherlands. pleurs@soz.nlAIMS: To study heparin-stimulated TFPI release in relation to complications in Type 1 diabetic patients. SUBJECTS AND METHODS: Nineteen uncomplicated Type 1 diabetic patients (group I) were compared with 18 patients with retinopathy (group II), and nine patients with retinopathy and albuminuria (group III). Blood samples were taken before (basal) and till 30 min after 5000 IU of heparin i.v. (post-heparin). TFPI activity was measured chromogenically. Von Willebrand factor, tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1) and thrombomodulin were also measured. RESULTS: Basal TFPI activity was higher in group III (121 +/- 10%) compared with group II (111 +/- 8%) or group I (110 +/- 13%) (P < 0.05), and strongly correlated with albuminuria (r = 0.66, P < 0.05). At all time points after heparin administration, TFPI activity in group III was significantly higher than in group I. TFPI activity was also higher in group III than in group II 5-30 min post-heparin. The increase in post-heparin TFPI activity, measured as the incremental area under the curve, was higher in group III compared with group I (65 +/- 7 vs. 59 +/- 4; P < 0.05). Of the other parameters, only thrombomodulin was higher in group III (44 +/- 24 vs. 26 +/- 7 (group II) and 28 +/- 9 ng/ml (group I); P < 0.01). CONCLUSIONS: We conclude that basal and post-heparin TFPI activity is increased in albuminuric patients. The increase in heparin-stimulated TFPI release in patients with albuminuria is higher than in patients with retinopathy or without complications. This could be the result of altered endothelial glycosaminoglycan characteristics.
Databáze: OpenAIRE
Externí odkaz: